Platelet-instructed SPP1

CP: Immunology CXCL4 PF4 SPP1 SPP1 macrophages chronic kidney disease fibrosis heart failure innate immunity myocardial infarction platelets

Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
28 02 2023
Historique:
received: 06 05 2022
revised: 11 11 2022
accepted: 31 01 2023
medline: 4 10 2023
pubmed: 23 2 2023
entrez: 22 2 2023
Statut: ppublish

Résumé

Fibrosis represents the common end stage of chronic organ injury independent of the initial insult, destroying tissue architecture and driving organ failure. Here we discover a population of profibrotic macrophages marked by expression of Spp1, Fn1, and Arg1 (termed Spp1 macrophages), which expands after organ injury. Using an unbiased approach, we identify the chemokine (C-X-C motif) ligand 4 (CXCL4) to be among the top upregulated genes during profibrotic Spp1 macrophage differentiation. In vitro and in vivo studies show that loss of Cxcl4 abrogates profibrotic Spp1 macrophage differentiation and ameliorates fibrosis after both heart and kidney injury. Moreover, we find that platelets, the most abundant source of CXCL4 in vivo, drive profibrotic Spp1 macrophage differentiation. Single nuclear RNA sequencing with ligand-receptor interaction analysis reveals that macrophages orchestrate fibroblast activation via Spp1, Fn1, and Sema3 crosstalk. Finally, we confirm that Spp1 macrophages expand in both human chronic kidney disease and heart failure.

Identifiants

pubmed: 36807143
pii: S2211-1247(23)00142-0
doi: 10.1016/j.celrep.2023.112131
pmc: PMC9992450
pii:
doi:

Substances chimiques

Ligands 0
Osteopontin 106441-73-0
Platelet Factor 4 37270-94-3
SPP1 protein, human 0
PF4 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

112131

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Konrad Hoeft (K)

Division of Nephrology and Clinical Immunology, RWTH Aachen University, Aachen, Germany; Institute of Experimental Medicine and Systems Biology, RWTH Aachen University, Aachen, Germany.

Gideon J L Schaefer (GJL)

Division of Nephrology and Clinical Immunology, RWTH Aachen University, Aachen, Germany; Institute of Experimental Medicine and Systems Biology, RWTH Aachen University, Aachen, Germany.

Hyojin Kim (H)

Institute of Experimental Medicine and Systems Biology, RWTH Aachen University, Aachen, Germany.

David Schumacher (D)

Institute of Experimental Medicine and Systems Biology, RWTH Aachen University, Aachen, Germany; Department of Anesthesiology, RWTH Aachen University, Aachen, Germany.

Tore Bleckwehl (T)

Institute of Experimental Medicine and Systems Biology, RWTH Aachen University, Aachen, Germany.

Qingqing Long (Q)

Institute of Experimental Medicine and Systems Biology, RWTH Aachen University, Aachen, Germany.

Barbara Mara Klinkhammer (BM)

Department of Pathology, RWTH Aachen University, Aachen, Germany.

Fabian Peisker (F)

Institute of Experimental Medicine and Systems Biology, RWTH Aachen University, Aachen, Germany.

Lars Koch (L)

Division of Nephrology and Clinical Immunology, RWTH Aachen University, Aachen, Germany; Institute of Experimental Medicine and Systems Biology, RWTH Aachen University, Aachen, Germany.

James Nagai (J)

Institute for Computational Genomics, RWTH Aachen University Hospital, Aachen, Germany; Joint Research Center for Computational Biomedicine, RWTH Aachen University Hospital, Aachen, Germany.

Maurice Halder (M)

Institute of Experimental Medicine and Systems Biology, RWTH Aachen University, Aachen, Germany.

Susanne Ziegler (S)

Institute of Experimental Medicine and Systems Biology, RWTH Aachen University, Aachen, Germany.

Elisa Liehn (E)

Institute for Molecular Medicine, University of South Denmark, Odense, Denmark.

Christoph Kuppe (C)

Division of Nephrology and Clinical Immunology, RWTH Aachen University, Aachen, Germany; Institute of Experimental Medicine and Systems Biology, RWTH Aachen University, Aachen, Germany.

Jennifer Kranz (J)

Institute of Experimental Medicine and Systems Biology, RWTH Aachen University, Aachen, Germany; Department of Urology, RWTH Aachen University, Aachen, Germany; Department of Urology and Kidney Transplantation, Martin-Luther-University, Halle (Saale), Germany.

Sylvia Menzel (S)

Institute of Experimental Medicine and Systems Biology, RWTH Aachen University, Aachen, Germany.

Ivan Costa (I)

Institute for Computational Genomics, RWTH Aachen University Hospital, Aachen, Germany; Joint Research Center for Computational Biomedicine, RWTH Aachen University Hospital, Aachen, Germany.

Adam Wahida (A)

Institute of Metabolism and Cell Death, Helmholtz Zentrum München, Neuherberg, Germany; Division of Gynecological Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany.

Peter Boor (P)

Division of Nephrology and Clinical Immunology, RWTH Aachen University, Aachen, Germany; Department of Pathology, RWTH Aachen University, Aachen, Germany.

Rebekka K Schneider (RK)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Department of Cell Biology, Institute for Biomedical Technologies, RWTH Aachen University, Aachen, Germany.

Sikander Hayat (S)

Institute of Experimental Medicine and Systems Biology, RWTH Aachen University, Aachen, Germany.

Rafael Kramann (R)

Division of Nephrology and Clinical Immunology, RWTH Aachen University, Aachen, Germany; Institute of Experimental Medicine and Systems Biology, RWTH Aachen University, Aachen, Germany; Department of Internal Medicine, Nephrology and Transplantation, Erasmus Medical Center, Rotterdam, the Netherlands. Electronic address: rkramann@gmx.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH